Abstract: A portable power system, including: at least one battery comprising a first plurality of battery cells; a direct current (DC) to alternating current (AC) inverter; at least two battery chargers; an AC input; a plurality of AC outputs; a plurality of sensors; a heating pad; at least one foam pad; at least one fan; a main control printed circuit board (PCB); a battery management system (BMS); and at least a first clamp enclosure housing at least a first set of components of the system.

Abstract: Provided is a battery system, including: at least two batteries, each battery comprising a battery management system; a plurality of sensors for sensing battery operation data; at least one external connection port; wherein: at least two battery management systems of the at least two batteries are coupled to the at least one external connection port; and at least two battery management systems of the at least two batteries store machine-executable instructions, that when executed, cause the at least one battery management system to communicate battery operation data to at least one external load.

Abstract: A battery pack and methods of operating the same are provided. The battery pack includes a battery, at least one sensor configured to read battery operation data, an external connection port, and a battery management system. The battery management system is coupled to the external and stores machine-executable instructions that, when executed, cause the battery management system to communicate battery operation data collected from the battery to an external load.

Abstract: The method of electrically powering a high frequency tool with a battery pack having a DC electrical output can include stepping up the battery pack DC electrical output to a high voltage DC output of above 200V; converting the high voltage DC output to 3 phase alternating current; and powering the high frequency tool using the 3 phase alternating current.

Abstract: The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.

Abstract: The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.

Abstract: A compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and n are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal product containing the same for treating a mammal afflicted with a disorder connected with peroxydation processes and biosynthesis of eicosanoids.

Abstract: A compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and n are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base,and medicinal product containing the same for treating a mammal afflicted with a disorder connected with peroxydation processes and biosynthesis of eicosanoids.

Abstract: The invention relates to a compound selected from those of formula (I): ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and X are as defined in the description, its Z and E isomers, its optical isomers, in pure form or in the form of a mixture, and its addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful in treating a disorder resulting from or associated with peroxidation phenomena, disturbances in eicosanoid synthesis, or with platelet aggregation disorders.

Abstract: A compound selected from those of formula (I): ##STR1## with R.sub.1, R.sub.2 and n as defined in the description, and medicinal products containing the same useful in treating or in preventing a disorder resulting from cellular damages following upon ischemia, hypoxia, or anoxia.

Abstract: A compound selected from those of the formula I: ##STR1## in which: R.sub.1 represents hydrogen or alkyl having 1 to 3 inclusive carbon atoms,R represents hydrogen, alkyl having 1 to 4 inclusive carbon atoms, or acyl --CO--R' in which R' represents alkyl having 1 to 4 inclusive carbon atoms,X represents O or H.sub.2,an isomer,and an addition salt thereof with a pharmaceutically-acceptable acid or base, andmedicinal products containing the same which are useful in treating or in preventing disorder resulting from or associated with phenomena of peroxidation and disturbance of the synthesis of eicosanoids.

Abstract: Compounds of general formula (I): ##STR1## where R.sub.1, R.sub.2, R.sub.4, A and B are defined in the description. Medicinal products.